Mitsugu Omasa

About

Dr. Mitsugu Omasa is a leading thoracic surgeon whose research focuses on the intersection of advanced immunotherapy and minimally invasive surgical techniques for lung cancer and mediastinal tumors. His most impactful work investigates the novel role of salvage surgery following immune checkpoint inhibitor (ICI) therapy for initially unresectable non-small cell lung cancer (NSCLC). This landmark 2024 study, which has already garnered significant attention, provides critical insights into the characteristics and outcomes of patients who undergo surgery after ICI treatment, helping to define a new treatment paradigm for advanced disease. Dr. Omasa also contributes to national standards, co-authoring the 2024 Japan Lung Cancer Society Medical Practice Guidelines for thymic epithelial tumors. Demonstrating his commitment to technical innovation, he has pioneered the use of robot-assisted thoracoscopic surgery (RATS) in the prone position for posterior mediastinal tumors, an approach that optimizes visualization and access in confined surgical spaces. Through his work on clinical guidelines and cutting-edge surgical robotics, Dr. Omasa is shaping the future of thoracic oncology.

Research Focus

Key Achievements

Top Papers

1. 1
   Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer

   6 citations · 2024
2. 2
   Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors – Summary of recommendations

   2 citations · 2025
3. 3
   Robot-Assisted Thoracoscopic Surgery (RATS) in the Prone Position for a Posterior Mediastinal Tumor

   1 citations · 2025

Key Collaborators

Contact & Links